Key result
Higher arginine vasopressin levels are linked to ~61% greater risk of death or HF admissions.
Why the study?
The role of arginine vasopressin in HFpEF and its association with atrial natriuretic peptide levels and cardiac remodeling in heart failure are not well understood.
Observational (n=124)
Arginine vasopressin is elevated in HFpEF and is independently associated with left ventricular hypertrophy, paradoxically low ANP levels, and an increased risk of death or heart failure admission.
AVP levels should not guide HFpEF management; leaves open whether vasopressin antagonism improves outcomes.
AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09-0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = -0.23; 95% CI = -0.42 to -0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09-0.43; P = 0.003) and with an increased risk of death or HF admissions during follow-up (hazard ratio = 1.61; 95% CI = 1.13-2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess.
No takes yet. Share an insight, caveat, or question.
Chirinos et al. (2018) conducted an observational in Heart failure (n=124). Arginine vasopressin (AVP) levels vs. Lower AVP levels was evaluated on Death or heart failure admissions during follow-up (HR 1.61, 95% CI 1.13-2.29, p=0.008). Higher arginine vasopressin levels were independently associated with an increased risk of death or heart failure admissions during follow-up (HR 1.61; 95% CI 1.13-2.29; P=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: